Advertisement
UK markets close in 7 hours 58 minutes
  • FTSE 100

    8,358.11
    +4.06 (+0.05%)
     
  • FTSE 250

    20,480.92
    -11.07 (-0.05%)
     
  • AIM

    781.92
    +2.09 (+0.27%)
     
  • GBP/EUR

    1.1621
    -0.0002 (-0.02%)
     
  • GBP/USD

    1.2478
    -0.0019 (-0.15%)
     
  • Bitcoin GBP

    49,245.55
    -612.98 (-1.23%)
     
  • CMC Crypto 200

    1,311.13
    +11.03 (+0.85%)
     
  • S&P 500

    5,187.67
    -0.03 (-0.00%)
     
  • DOW

    39,056.39
    +172.13 (+0.44%)
     
  • CRUDE OIL

    79.41
    +0.42 (+0.53%)
     
  • GOLD FUTURES

    2,318.90
    -3.40 (-0.15%)
     
  • NIKKEI 225

    38,073.98
    -128.39 (-0.34%)
     
  • HANG SENG

    18,522.95
    +209.09 (+1.14%)
     
  • DAX

    18,548.04
    +49.66 (+0.27%)
     
  • CAC 40

    8,132.32
    +0.91 (+0.01%)
     

Risankizumab Could Be AbbVie’s Long-Term Growth Driver

Risankizumab Could Be AbbVie’s Long-Term Growth Driver

In December 2017, AbbVie (ABBV) announced positive top-line results for its pivotal Phase 3 IMMhance trial to evaluate the safety and efficacy of risankizumab 150 mg1 for the treatment of individuals with moderate-to-severe plaque psoriasis.